Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

81.10 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,081
Open 81.10
Bid (Size) 84.54 (1)
Ask (Size) 84.59 (1)
Prev. Close 81.10
Today's Range 81.10 - 81.10
52wk Range 78.17 - 148.15
Shares Outstanding N/A
Dividend Yield 1.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 inhibitors with potential for other diseases. 
Via Benzinga

Performance

YTD
-7.34%
-7.34%
1 Month
-7.18%
-7.18%
3 Month
-28.81%
-28.81%
6 Month
-36.57%
-36.57%
1 Year
-22.92%
-22.92%

More News

Read More
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
Via MarketBeat
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Via The Motley Fool
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
Novo Nordisk Unusual Options Activity
Via Benzinga
Not A Turnaround But Could Be Soon Novo Nordisk
Via Talk Markets
Topics Stocks / Equities
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
5 Stocks to Buy Now for Big Returns in 2025
Via The Motley Fool
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss
Via Benzinga
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Via Stocktwits
Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts
Via Investor's Business Daily
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Via Investor's Business Daily
Topics Government
Exposures Political
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Via The Motley Fool
Topics Government
Exposures Political
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
Via Investor's Business Daily
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity
Via MarketBeat
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.